Menu ×

HEALTHCARE & PHARMACEUTICAL

Blastomycosis Treatment Market Segmentation by Anatomy (Lung, Bones, Central Nervous System, and Others); by Treatment {Medication (Itraconazole, Amphotericin B, and Others), and Surgery}; and by End-User (Hospital, Pharmacy, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Blastomycosis Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • February, 2021: Sandoz announced the acquisition of cephalosporin antibiotics business of GSK, to expand its portfolio to production of antimicrobial drugs.

  • September, 2020: Mylan and Pfizer received approval from European Commission for consolidation of Mylan and Upjohn for distribution in Europe.

Global Blastomycosis Treatment Market Highlights over 2022 – 2030

The global blastomycosis treatment market is estimated to grow at a CAGR of ~3.5% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing cases of fungal infections, backed by poor immune system in majority of the people. Blastomycosis is caused by a fungus, Blastomyces, which is found in soil and decomposing organic matter. The infection is caused by inhalation of fungal spores, which primarily infects the lungs and respiratory tract. People with poor immunity are at higher risk of infection or severe infection. Poor lifestyle, unhealthy eating habits, unhygienic surroundings, and growing prevalence of lifestyle diseases are some of the major factors promoting the weakening of immune system. Moreover, growing prevalence of drug-resistant fungal infections is estimated to boost the demand for development of new anti-fungal drugs, which, in turn, is projected to boost the market growth. According to the World Health Organization, drug resistance in fungi is a silent crisis, which needs to be addressed globally. Government initiatives, such as, World Antimicrobial Awareness Week started in November 2020 by the WHO, and Global Antimicrobial Resistance and Use Surveillance System (GLASS) launched in 2015, are estimated to strengthen the market growth.

Blastomycosis Treatment Market GraphIncreasing health awareness amongst individuals globally, is a major factor estimated to boost the market growth. The government is constantly investing to improve the healthcare facilities for the public. Healthcare expenditure has witnessed major growth in the past decade, which is another factor foreseen to drive the market growth. According to the data by the World Bank, the global per capita healthcare expenditure had touched USD 1,111.082 in 2018. CLICK TO DOWNLOAD SAMPLE REPORT

Healthcare

The global blastomycosis treatment market is segmented by anatomy into lung, bones, central nervous system, and others, out of which, the lung segment is anticipated to hold the largest share in the market over the forecast period on account of increasing cases of lung infection of blastomycosis, as lung is the first organ to come in contact with the fungus. In severe cases, infection reaches the bones and other parts of the body, which is rare.

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita image

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Blastomycosis Treatment Market Regional Synopsis

On the basis of geographical analysis, the global blastomycosis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to attain modest growth over the forecast period on the back of poor immunity, and high prevalence of lifestyle diseases. The improving healthcare sector, and economic development in the APAC region is also estimated to boost the market growth.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the higher prevalence of blastomycosis, along with other fungal infections, in the United States and Canada. According to the data by the U.S. Center of Disease Control and Prevention (CDC), occurrence of blastomycosis varies from region to region, and can go as high as 10-40 cases per 100,000 individuals in some regions of the U.S.

Blastomycosis Treatment Market Share Graph

The global blastomycosis treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global blastomycosis treatment market includes the following segments:

By Anatomy

  • Lung
  • Bones
  • Central Nervous System 
  • Others

By Treatment

  • Medication
    • Itraconazole
    • Amphotericin B
    • Others
  • Surgery

By End-User

  • Hospital
  • Pharmacy
  • Others

Growth Drivers

  • Increasing Cases of Fungal Infections
  • Poor Immunity and Lifestyle of People Globally
  • Rising Concerns Regarding Anti-Microbial Resistance

Challenges

  • Difficult Diagnosis of Blastomycosis
  • Increasing Circulation of Generic Drugs in the Market

Top Featured Companies Dominating the Market

  • Emcure Pharmaceuticals Limited
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Viatris Inc.
  • Hindustan Antibiotics Limited
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sanofi-aventis Groupe
  • Abbott Laboratories
  • Merck & Co., Inc.
  • Siemens Healthcare GmbH
  • Pfizer Inc.

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved